Co-PSMA abstract accepted for oral presentation at EAU
Filed with ASX · · 4 pages · English
Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)1 Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent’s Hospital Sydney, for ora
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Positive guidance from the US FDA on Cu-64 SARTATE Phase III
- AGM MD Presentation
- Clarity signs copper-67 Supply Agreement with Nusano
- Co-PSMA trial achieves primary endpoint
- S&P DJI Announces September 2025 Quarterly Rebalance
Later from Clarity Pharmaceuticals
- Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
- SECuRE trial to continue with no modifications to protocol
- SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
- Quarterly Activities/Appendix 4C Cash Flow Report
- Co-PSMA abstract released
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals